Clelia Cortile

Clelia Cortile

Auto-generated profile, based on publicly available information

Clelia Cortile

Gene Expression and Cancer Models Unit, Department of Research and Advanced Technologies Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in The EMBO Journal
Verified
Journal Article
Open access
TBTiziana Bruno
Tiziana Bruno
GCGiacomo Corleone
Giacomo Corleone
VCValeria Catena
Valeria Catena
CCClelia Cortile
Clelia Cortile
FNFrancesca De Nicola
Francesca De Nicola
MFMaurizio Fanciulli
Maurizio Fanciulli
Several kinds of stress promote the formation of three‐stranded RNA:DNA hybrids called R‐loops. Insufficient clearance of these structures promotes genomic instability and DNA damage, which ultimately contribute to the establishment of cancer phenotypes. Paraspeckle assemblies participate in R‐loop resolution and preserve genome stability, however, the main determinants of this mechanism are still unknown. This study finds that in Multiple Myeloma (MM), AATF/Che‐1 (Che‐1), an RNA‐binding protein fundamental to transcription regulation, interacts with paraspeckles via the lncRNA NEAT1_2 (NEAT1) and directly localizes on R‐loops. We systematically show that depletion of Che‐1 produces a marked accumulation of RNA:DNA hybrids. We provide evidence that such failure to resolve R‐loops causes sustained activation of a systemic inflammatory response characterized by an interferon (IFN) gene expression signature. Furthermore, elevated levels of R‐loops and of mRNA for paraspeckle genes in patient cells are linearly correlated with Multiple Myeloma progression. Moreover, increased interferon gene expression signature in patients is associated with markedly poor prognosis. Taken together, our study indicates that Che‐1/NEAT1 cooperation prevents excessive inflammatory signaling in Multiple Myeloma by facilitating the clearance of R‐loops. Further studies on different cancer types are needed to test if this mechanism is ubiquitously conserved and fundamental for cell homeostasis.

17 February 2024 in Leukemia
Verified
Journal Article
Open access
PDF file
TBTiziana Bruno
Tiziana Bruno
VCValeria Catena
Valeria Catena
GCGiacomo Corleone
Giacomo Corleone
CCClelia Cortile
Clelia Cortile
MCMaria Chiara Cappelletto
Maria Chiara Cappelletto
Silvia Di AgostinoSilvia Di Agostino
Silvia Di Agostino

11 December 2025 in Blood
Verified
Journal Article
Open access
TBTiziana Bruno
Tiziana Bruno
MCMaria Chiara Cappelletto
Maria Chiara Cappelletto
CCClelia Cortile
Clelia Cortile
SGStefano Di Giovenale
Stefano Di Giovenale
BABruno Amadio
Bruno Amadio
GCGiacomo Corleone
Giacomo Corleone
Multiple myeloma (MM) continues to be an incurable malignancy, even with recent therapeutic advancements. Although epigenetic dysregulation at cis-regulatory elements is known to drive disease progression, the complete molecular mechanisms underlying these alterations are poorly understood. Using Assay for Transposase-Accessible Chromatin with high-throughput sequencing analysis combined with the computational footprinting of CD138+ cells from 55 patients with MM, we depicted the dynamic changes in chromatin accessibility during disease progression and identified nuclear respiratory factor 1 (NRF1) as a master regulator of vital MM survival pathways. We demonstrated that NRF1 maintains proteasome homeostasis by orchestrating the ubiquitination pathway, which is essential for MM cell survival. We discovered a novel enhancer element that physically interacts with the NRF1 promoter, sustaining its expression. Targeting this enhancer RNA reduced NRF1 levels and increased tumor cell sensitivity to bortezomib (BTZ), suggesting therapeutic potential. In xenograft models, we showed that antisense oligonucleotides targeting the NRF1 enhancer, either alone or combined with BTZ, significantly decreased tumor burden and improved survival. Our findings reveal a previously unknown NRF1-dependent mechanism regulating MM cell survival and present a promising therapeutic approach through the manipulation of its regulatory network.